|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||90.15 - 90.65|
|52-week range||72.98 - 93.58|
|Beta (5Y monthly)||0.46|
|PE ratio (TTM)||28.44|
|Forward dividend & yield||3.43 (3.80%)|
|Ex-dividend date||09 Mar 2023|
|1y target est||N/A|
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.
The stock market is in a precarious place. The sharp rise in both interest rates and bond yields has weighed heavily on most stocks since the first quarter of 2022. The top-shelf drugmakers Novartis (NYSE: NVS) and Vertex Pharmaceuticals (NASDAQ: VRTX) are two prime examples.
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.